Kornimate/medical-research-clean huggingface dataset:
video capsule endoscopy for detection of gastrointestinal bleeding in the small bowel

Conditions: GastroIntestinal Bleeding

Summary: small bowel capsule endoscopy is the main diagnostic standard for small bowel bleeding. this study investigates the detection rate of small bowel bleeding in capsule endoscopy and further endoscopic treatment in a prospective and retrospective cohort.

small bowel capsule endoscopy is considered the diagnostic gold standard in the diagnosis of diseases of the small bowel. most indications for capsule endoscopy are overt small bowel bleedings - defined as gastrointestinal bleeding after negative gastroscopy and colonoscopy - or occult iron deficiency anemia. timing of small bowel capsule endoscopy seems to be decisive for the diagnosis of small bowel bleeding: corresponding to the actual guidelines the detection of small bowel bleeding can be up to \> 70% if the intervention is performed within 2 days. treatment of small bowel bleedings can be performed with small bowel enteroscopy such as balloon or motorized spiral enteroscopy. against this background this study investigates the rate of small bowel bleeding diagnosed in capsule endoscopy. the aim of the study is to report tumorous, vascular and inflammatory findings as well as complications and cecal accessibility. one focus of the study is the time between small bowel bleeding and small bowel capsule endoscopy and small bowel enteroscopy, respectively. endoscopic therapies and further bleeding episodes are recorded. in order to determine the improved clinical outcome after the introduction of the shortened timing for recommendation published in 2022, a retrospective cohort should be included in addition to a prospective cohort.

Eligibility criteria:
inclusion criteria: * suspicion of gastrointestinal bleeding in the small bowel undetected by gastroscopy and colonoscopy * informed consent exclusion criteria: * contraindications for small bowel capsule endoscopy (e.g. stenosis)

Keywords: small bowel capsule endoscopy gastrointestinal bleeding anticaogulation
a study of risk factors for anti-erythropoietin antibody positive pure red cell aplasia among patients with chronic kidney disease receiving epoetin alfa

Conditions: Pure Red-cell Aplasia

Summary: the purpose of this study is to collect historical occurrences of risk factors that are potentially associated with the development of anti-erythropoietin (epo) antibody positive pure red cell aplasia (prca) in participants with chronic kidney disease who have been recently treated with epoetin alfa (eprex).

this is a multicenter (study conducted at multiple sites), case-control (study that compare individuals with a disease or condition \[cases\] to a group of individuals without the disease or condition \[controls\] to determine the possible factor which increased disease incidence), retrospective (a study in which the participants are identified and then followed backward, as time passes) study. retrospective risk factor data will be collected for control participants matched to the subset of participants in protocol epo-imu-301 identified as having chronic kidney disease and anti-epo antibody positive prca that began while the participant was receiving treatment with eprex (index participants). for each index participant, up to 4 matched non-prca control participants with chronic kidney disease will be enrolled in this study. approximately 600 control participants will be enrolled in this study. control participants will be selected from the same site as the index participant and the data will be collected from the date closest to the reference date (loss of efficacy \[drop in hemoglobin of greater than 2 g/dl/month\] was first seen) that the control participant satisfies all study inclusion and exclusion criteria. the optional pharmacogenomic part (testing for polymorphisms and haploid types of the erythropoietin gene) will be recorded for the control participants who will sign the pharmacogenomics part of the study. no drug administration or treatment will be mandated by this study. safety evaluation will include assessment of adverse events.

Eligibility criteria:
inclusion criteria: * history of anemia due to chronic kidney disease * pure red cell aplasia (prca) associated with erythropoietin-alpha (epo) treatment * treatment with epo for a minimum of 2 months occurring within more or less 3 months of the reference date (date of loss of efficacy \[drop in hemoglobin of greater than 2 g/dl/month\] was first observed) exclusion criteria * history of and information related to past exposure to epo not available * history of prca or anti-epo antibody positive status before or after the reference date

Keywords: pure red-cell aplasia chronic kidney failure epoetin alfa (eprex) erythropoietin kidney disease anemia
routine therapy plus moxifloxacin in advanced breast cancer

Conditions: Advanced Breast Cancer; Antibiotic; Stable Disease With a Trend of Progression

Summary: this is a phase ii,single center,prospective, single arm clinical trial. the objective is to evaluate the efficacy and safety of routine therapy plus moxifloxacin in advanced breast cancer whose evaluation is stable disease with a trend of progression.

this is a phase ii,single center,prospective, single arm clinical trial. a lot of in vitro and in vivo study demonstrate that quinolones antibiotics can increase anti-tumor effect. the objective is to evaluate the efficacy and safety of routine therapy plus moxifloxacin in advanced breast cancer whose evaluation is stable disease with a trend of progression.

Eligibility criteria:
inclusion criteria: * female ≥ 18 years, ≤70 years. * has measurable metastatic mbc, with at least 1 measurable lesion per recist criteria. * fail first-line or above anti-tumor treatment * evaluation is stable disease with a trend of progression. * minimum life expectancy 16 weeks * histological confirmation of breast cancer on primary tumour at diagnosis/on biopsy of metastasis * ecog performance status (ps) 0-2 with no deterioration over previous 2 weeks * normal organ function. * has signed a patient informed consent form exclusion criteria: * hypersensitivity to moxifloxacin or other quinolones. * tendon damage,peripheral neuropathy,myasthenia gravis. * rapidly progressive visceral disease not suitable for further therapy. * evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension, active bleeding diatheses, or active infection including hepatitis b, hepatitis c and hiv * with the exception of alopecia, any unresolved toxicities from previous therapy greater than ctcae grade 1 before study treatment * evidence of dementia, altered mental status or any psychiatric condition that would prohibit understanding or rendering of informed consent * inability or unwillingness to comply with study procedures, including inability to take regular oral medication * researchers consider it is not suitable for participation.
a pilot study for pharmacokinetic parameter of colchicine in patient taking rifampin

Conditions: Chronic Kidney Disease; Tuberculosis

Summary: the purpose of this study is to examine the colchicine concentration before and after the administration of rifampicin.


Eligibility criteria:
inclusion criteria: * from 18yrs to 80yrs , man and women * the patient who are taking rifampicine over 2weeks * the patient sign on the concent form exclusion criteria: * the patient have experience to take medication that have an effect on renal function * the patient have hypersensitivity to colchicine * at least, the average level of two separate blood pressure ( 2min interval ) shows that sbp \ =160 mmhg and dbp \ =100 mmhg, or heart rate \ 90 beats/min * uncontrolled hypertension * serum albumin \ 5 g/dl * acute hepatitis or the level of ast or alt is over 2times of normal range or the level of bilirubin is over 2.0 mg/dl * the patient who have gastro-intestinal disease ( ex, crohn's disease, acute or chronic pancreatitis, ulcer )or who have the surgical history of gastrointestine. * the patient who should take azathioprine, mercaptopurine, cyclophosphamide, losartan, benzbromarone,fenofibrate,furosemide ,probenecid * the patient who had taken part in the other study within 3months * the patient who had gotten blood transfusion * pregnant, breast feeding
determining the effect of telephone counseling service provided to primiparous mothers on postpartum depression

Conditions: Depression, Postpartum

Summary: the aim of this study is to determine the effect of telephone counseling services provided to primiparous mothers on postpartum depression. hypotheses h01; there is no difference between the postpartum depression score of the telephone counseling services group and the postpartum depression score of the control group. the study will be carried out in two different groups. the practice will start with meeting the women who give birth will be visited by the researcher at the postpartum clinic at least 6 hours after normal birth and 12 hours after cesarean births. after the women are evaluated in terms of eligibility criteria for the research, the women who are eligible will be informed about the research and written informed consent will be obtained from the women who accept. the random distribution of women to the study groups will be carried out using the block randomization method. the following applications will be made to the groups. the researcher will contact the experimental group by phone. he will introduce herself and 6 weeks (during postpartum). it will provide the mother with the consultancy service she needs about herself and the newborn 24 hours a day. after 6 weeks, the training will end and the third researcher will make post-tests of the depression scale to both groups without knowing the experimental and control groups.


Eligibility criteria:
inclusion criteria: * primiparous women * agreeing to participate in the research and obtaining written permission, * no hearing or vision problems exclusion criteria: * multiparous women
radiochemotherapy and interventional radiotherapy in vaginal cancer

Conditions: Vaginal Cancer

Summary: prospective observational multicenter study, aimed at evaluating the effectiveness on local control and cancer-specific survival of radiochemotherapy followed by interventional radiotherapy in patients affected by vaginal cancer

prospective observational multicenter study, aimed at evaluating the effectiveness on local control and cancer-specific survival of radiochemotherapy (45gy on pelvis and tumor plus chemotherapy with cisplatinum) followed by interventional radiotherapy (28gy on residual tumor) in patients affected by vaginal cancer

Eligibility criteria:
inclusion criteria: * age more than18 years old * performance status 0,1 * hystological diagnosis of squamous vaginal cancer * hpv, p16, p53 status * stage i, ii, iii and iv (ajcc 2018th version) * stadiation with magnetic resonance and positron emission tomography * informed consensus exclusion criteria: * age inferior 18 years old * performance status more than 2 * previous cancer in the last ten years * previous radiation treatment in the region of interest * presence of pathologies that contraindicate radiotherapy treatment (genetic syndromes of hyper-radiosensitivity, ulcerative colitis, diverticulitis in the acute phase, severe diverticulosis, chronic pelvic inflammation) * presence of internal pathologies that contraindicate chemotherapy or radio-chemotherapy treatment (severe liver disease, heart disease, renal failure, etc.) * presence of distant metastases in sites other than the pelvic lymph nodes * any significant medical condition that in the opinion of the investigator may interfere with the patient's optimal participation in the study
epigenetic reprogramming of monocytes in patients with coronary atherosclerosis

Conditions: Atherosclerosis

Summary: in this study, the investigators will determine whether patients with documented atherosclerosis are characterized by specific epigenetic changes in circulating cells of the innate immune system, compared to patients without atherosclerosis.

rationale: the innate immune system plays a pivotal role in the development and progression of atherosclerosis. recently, it was reported that monocytes can develop a long-lasting immunological memory after stimulation with various microorganisms, which has been termed 'trained innate immunity'. this memory is induced by epigenetic reprogramming. we hypothesize that trained monocytes augment atherogenesis. objective: the main objective is to study whether patients with coronary atherosclerosis show specific epigenetic changes in the promoter regions of pro-inflammatory cytokines and chemokines and whether this correlates with the inflammatory phenotype of these cells. study design: observational study study population: adult patients who have had computed tomography coronary angiography because of chest pain: 20 patients without atherosclerosis and 20 patients with severe atherosclerosis will be included.

Eligibility criteria:
inclusion criteria: * patients (male/female), * aged \>18 years, * admitted to the acute coronary unit of the cwz hospital for evaluation of chest pain. * no coronary atherosclerosis * or severe atherosclerosis exclusion criteria: * signs or symptoms of a current infection (fever, chills) * auto-immune diseases (such as rheumatoid arthritis)
effects of chronic leucine supplemetion on glucose homeostasis, body compositin, muscle mass and strength of healthy and young subjects

Conditions: Effect of Chronic Leucine Supplementation on Glucose Homeostasis, Lipid Profile, Body Composition, and Muscle Mass and Strenght

Summary: this study aims to evaluate the effects of chronic leucine supplemetion on glucose homeostasis, body compositin, muscle mass and strength of healthy and young subjects


Eligibility criteria:
inclusion criteria: * non-smokers; * healthy; * non-users of dietary supplements and drugs * not engaged in any regular physical activity program exclusion criteria: * vegetarians
evaluation of medical device

Conditions: Acute Infectious Diseases

Summary: a preliminary study was conducted from 01/26/2015 to 10/26/2015 on 605 patients admitted to mia with an intravenous and/or a urinary catheter. the investigators analyzed: * the demographic characteristics of the patient * the final diagnosis * the patient's severity and the patient outcome after discharge from mia * the justification of the venous and or a urinary catheter * the duration of the prescription of the device evaluation on admission of the need to maintain an intravenous or urinary catheter. adjusting the prescription in terms of duration or withdrawal of the device in order to limit their complications (lymphangitis, superficial thrombophlebitis, bacteremia related to health care, urinary tract infection). hypothesis: limit the length of stay and reduce the cost of hospitalization.


Eligibility criteria:
inclusion criteria: * patient with an intravenous catheter and/or a urinary catheter. * patient is more than 18 years old. * patient who accepts to have his medical records reviewed for research. * patient with health insurance exclusion criteria: * refusal of participation in the study
at247, novolog® and fiasp® administered via continuous subcutaneous infusion in glucose clamp study

Conditions: Diabetes Mellitus, Type 1

Summary: phase 1 randomized, double-blind, three period, crossover study comparing the pharmacodynamic, pharmacokinetic, safety and tolerability profiles for arecor ultra-rapid insulin aspart (at247), novolog® and fiasp® in participants with type 1 diabetes mellitus (t1dm) during continuous subcutaneous infusion (csii)


Eligibility criteria:
inclusion criteria: 1. subjects diagnosed with t1dm for at least 12 months. 2. subjects who have been using an approved insulin pump or use multiple daily injections with basal and bolus insulin, with a stable total insulin dose \<1.2 u/kg/day and bolus insulin dose \<0.7 u/kg/day for at least 3 months. 3. fasting c-peptide concentration of ≤0.3 nmol/l (0.9061 ng/ml), assessed at a plasma glucose concentration \>90 mg/dl. 4. hba1c concentration of ≤8.5% (≤69 mmol/mol). 5. bmi within the range ≥18.5 - ≤28.0 kg/m2. exclusion criteria: 1. known or suspected hypersensitivity to imp or related products. 2. history or presence of malignant neoplasms within the past 5 years prior to the day of screening. basal and squamous cell skin cancer and any in-situ carcinomas are allowed. 3. clinically significant concomitant disease including cardiovascular, renal, hepatic, respiratory, gastrointestinal, hematological, dermatological, neurological, psychiatric, systemic or infections disease as judged by the investigator. 4. supine blood pressure at screening (after resting for at least 5 min in supine position) outside the ranges for systolic 95-140 mmhg blood pressure and/or for diastolic blood pressure greater than 90 mmhg. 5. smoking more than 5 cigarettes per day or equivalent use of any tobacco containing product, and unable to refrain from smoking during the in-house periods of the study. a positive urine cotinine test at screening and check-in.
lymphoscintigraphy to detect early metastases in patients with cancer of the mouth or throat

Conditions: Head and Neck Cancer

Summary: rationale: new imaging procedures such as lymphoscintigraphy may improve the ability to detect the spread of mouth and throat cancer to lymph nodes in the neck. purpose: pilot study of lymphoscintigraphy followed by sentinel lymph node mapping and sentinel lymph node biopsy to detect lymph node metastases in the neck in patients who have mouth or throat cancer.

objectives: * evaluate the sensitivity of lymphoscintigraphy and isosulfan blue in localization of sentinel lymph nodes in patients with previously untreated squamous cell carcinoma of the oral cavity or oropharynx. * determine evidence of micrometastases in histologically normal sentinel lymph nodes resected from these patients. * assess the clinical significance of micrometastases in lymph nodes resected from these patients. outline: patients undergo preoperative lymphoscintigraphy utilizing technetium tc 99m sulfur colloid followed by intraoperative injections of isosulfan blue at 3-4 locations into the primary tumor periphery. once the afferent lymphatic channel and sentinel node have been identified, patients undergo cervical lymphadenectomy followed by resection of the primary tumor. resected primary tumor, radioactive lymph nodes, and blue-stained sentinel nodes are then subjected to molecular (polymerase chain reaction) and histocytochemical (immunohistochemistry for cytokeratin and micrometastases, light microscopy) analyses. patients are followed at 1, 3, 6, 12, 18, and 24 months. projected accrual: approximately 25 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: * histologically confirmed primary squamous cell carcinoma of the oral cavity or oropharynx * stage 0-iva (any t, n0) * no low-risk tumors * must require elective staging neck dissection and resection of primary tumor patient characteristics: age: * 18 to 70 performance status: * not specified life expectancy: * not specified hematopoietic: * not specified hepatic: * not specified renal: * not specified other: * not pregnant or nursing * no concurrent impaired mental status prior concurrent therapy: biologic therapy: * not specified chemotherapy: * no prior chemotherapy endocrine therapy: * not specified radiotherapy: * no prior radiotherapy surgery: * see disease characteristics * no prior surgery

Keywords: stage 0 oropharyngeal cancer stage 0 lip and oral cavity cancer stage i squamous cell carcinoma of the lip and oral cavity stage ii squamous cell carcinoma of the lip and oral cavity stage iii squamous cell carcinoma of the lip and oral cavity stage iv squamous cell carcinoma of the lip and oral cavity stage i squamous cell carcinoma of the oropharynx stage ii squamous cell carcinoma of the oropharynx stage iii squamous cell carcinoma of the oropharynx stage iv squamous cell carcinoma of the oropharynx
acute effects of glp-1 on renal hemodynamics

Conditions: The GLP-1-mediated Gut-kidney Axis

Summary: this study investigates the hypothesis, that glp-1's suppression of ang ii and natriuretic action increase medullary perfusion and decrease oxygen consumption, leading to higher tissue oxygenation.

human studies have recently demonstrated a significant natriuretic effect of glp-1 when the extracellular fluid volume (ecfv) is expanded by intravenous sodium-loading; in these studies, there was a suppression of ang ii with no change in net renal hemodynamics, pointing to a tubular mechanism for reduced nacl reabsorption secondary to the ang ii suppression. in the current randomized and controlled study, investigators aim to test the hypothesis that glp-1's suppression of ang ii and natriuretic action increase medullary perfusion and decrease oxygen consumption, leading to higher tissue oxygenation. thus, contributing to the renoprotective action of glp-1. under fixed sodium intake for 4 days before each study day, 10 healthy male participants will be investigated during a 1-hour infusion of glp-1 (1.5 pmol/kg/min) or vehicle together with an intravenous infusion of 0.9% nacl. interleaved measurements of raf, oxygenation (t2\*) and perfusion by arterial spin labeling in the renal cortex and medulla at fixed time points will be conducted, using magnetic resonance imaging (mri).

Eligibility criteria:
inclusion criteria: * normal health demonstrated by medical examination. * normal values for fasting plasma glucose, total cholesterol, triglyceride, hdl, ldl, creatinine, ast, alt and electrolyte concentrations. exclusion criteria: * immunosuppressive treatment for the previous 12 months. * alcohol abuse. * medical treatment with oral glucocorticoids, dipeptidyl peptidase-4 (dpp-4) inhibitors, or glp-1 receptor agonists that, in the opinion of the investigator, may interfere with glucose metabolism. * use of lithium. * medical treatment that affects insulin secretion or cardiovascular efficacy goals. * liver disease (alt\> 2 x normal value). * renal impairment (creatinine\> 130 µm and / or albuminuria). * severe claustrophobia. * mri incompatible foreign bodies.

Keywords: glucagon-like peptide-1 kidney renal hemodynamics renal blood flow